Trial Profile
An Open Label, Longitudinal Study of the Effects of Subcutaneous Acute and Chronic Pasireotide (SOM230) Therapy on Adrenocorticotrophic Hormone and Tumour Volume in Patients with Nelson's Syndrome.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary) ; Pasireotide (Primary)
- Indications Nelson's syndrome
- Focus Therapeutic Use
- 27 Jul 2020 This trial is completed in UK (Global End Date: 24 Sep 2015), according to European Clinical Trials Database record.
- 18 Nov 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to discontinued.
- 07 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.